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Insulin resistance and impaired glucose homoeostasis are
important indicators of Type 2 diabetes and are early risk
factors of AD (Alzheimer’s disease). An essential feature of AD
pathology is the presence of BACE1 (β-site amyloid precursor
protein-cleaving enzyme 1), which regulates production of toxic
amyloid peptides. However, whether BACE1 also plays a role
in glucose homoeostasis is presently unknown. We have used
transgenic mice to analyse the effects of loss of BACE1 on body
weight, and lipid and glucose homoeostasis. BACE1− / − mice are
lean, with decreased adiposity, higher energy expenditure, and
improved glucose disposal and peripheral insulin sensitivity than
wild-type littermates. BACE1− / − mice are also protected from
diet-induced obesity. BACE1-deficient skeletal muscle and liver
exhibit improved insulin sensitivity. In a skeletal muscle cell line,
BACE1 inhibition increased glucose uptake and enhanced insulin
sensitivity. The loss of BACE1 is associated with increased levels
of UCP1 (uncoupling protein 1) in BAT (brown adipose tissue)
and UCP2 and UCP3 mRNA in skeletal muscle, indicative
of increased uncoupled respiration and metabolic inefficiency.
Thus BACE1 levels may play a critical role in glucose and lipid
homoeostasis in conditions of chronic nutrient excess. Therefore
strategies that ameliorate BACE1 activity may be important
novel approaches for the treatment of diabetes.
Key words: β-site amyloid precursor protein-cleaving enzyme
1 (BACE1), glucose uptake, insulin sensitivity, liver, skeletal
muscle, uncoupling protein (UCP).
INTRODUCTION
There is a higher risk of sporadic AD (Alzheimer’s disease) in
patients with Type 2 diabetes and AD patients are more prone
to Type 2 diabetes [1,2]. Being obese or overweight in midlife
is also implicated as an independent risk factor of AD in later
life [3,4]. Furthermore, AD patients exhibit impaired glucose
metabolism, hyperinsulinaemia and insulin resistance [5,6], and
brains from AD patients display reduced insulin levels, insulin
receptor density and signalling [7,8]. AD patients with elevated
plasma insulin have reduced CSF (cerebrospinal fluid) insulin
levels [5,7] and lower brain glucose utilization [6]. In addition,
HFD (high-fat diet) induction of peripheral insulin resistance in
an AD transgenic mouse model reduced brain insulin and insulin
receptor signalling, and increased AD pathology [9]. Collectively
these data indicate that AD is closely associated with insulin
resistance, an outcome exacerbated by the presence of Type 2
diabetes and obesity.
A key feature of AD pathology development is the proteolytic
cleavage of APP (amyloid precursor protein) by γ - and β-
secretase [BACE1 (β-site amyloid precursor protein-cleaving
enzyme 1)], which raise levels of Aβs (β-amyloid peptides)
that aggregate to form extracellular amyloid plaques [10,11].
Importantly, deletion of BACE1 in APP transgenic mice abolishes
neuronal production of Aβ and deposition of amyloid plaques
[11–13]. Thus excessive levels and/or activity of BACE1 are
thought to be the primary driver for the neurodegeneration and
cognitive dysfunction associated with sporadic AD. Indeed,
increased BACE1 protein levels and activity have been reported
in brains from AD patients [14,15]. Neuronal BACE1 levels and
activity increase with age and following pathological events such
as oxidative stress, hypoxia and brain injury and are associated
with raised Aβ and an increased risk of AD [14–16]. Therefore
it is plausible that the insulin resistance and impaired glucose
metabolism associated with AD may be connected to raised
levels and activity of this enzyme.
BACE1 mRNA is expressed in non-neuronal tissues, although
at much lower levels than in the brain [17]. The pancreas
is an exception, although the high levels of mRNA comprise
three splice variants encoding BACE1 isoforms devoid of
β-secretase activity. The presence of BACE1 in skeletal muscle
and liver [18,19] raises the possibility that BACE1 activity in
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these tissues may also be up-regulated by stress conditions.
BACE1-deficient (BACE1− / − ) mice have been reported initially
not to show any adverse development, morphology, physiology or
gross behaviour [11–13]. However, later studies indicated subtle
behavioural changes with mild impairments in spatial learning
and memory [20], or a more timid and anxious phenotype were
reported [21]. Despite the link between AD, insulin resistance
and glucose homoeostasis deregulation in humans and rodents,
the involvement of BACE1 in whole-body glucose and energy
homoeostasis has not been investigated. In the present paper
we show that mice lacking BACE1 are lean, resistant to diet-
induced obesity, and display increased peripheral tissue insulin
sensitivity with improved whole-body glucose disposal. These
results delineate a novel aspect of BACE1 function in metabolic
homoeostasis and provide a possible functional link between the
levels of this key amyloid processing enzyme and the reciprocal
connection between AD and Type 2 diabetes.
MATERIALS AND METHODS
Animals
BACE1− / − mice were obtained from GlaxoSmithKline and were
continued on the C57Bl6/J background, providing BACE1− / −
and BACE1+ / − mice and WT (wild-type) littermates. Mice were
maintained on a 12 h light/dark cycle with free access to water and
standard rodent chow [7.5% fat, 75% carbohydrate and 17.5%
protein by energy (RM1 diet); Special Diet Services], except
where noted, and were housed singly in specific pathogen-free
barrier facilities. Genotyping of mice was performed by PCR
amplification of ear DNA with primers as described previously
[21]. All animal care protocols and procedures were performed
in accordance to the Animal Scientific Procedures Act (1986)
and with approval of the University of Dundee Animal Ethics
Committee. BACE1− / − and BACE1+ / − mice were studied with
appropriate age-matched littermate controls. For assessment
of fat and lean mass, a magnetic resonance analyser was used
(Echo Medical Systems). For HFD studies, mice were fed with
chow containing, by energy, 45% fat, 20% protein and 35%
carbohydrate (catalogue number 58V8, TestDiet®, Purina Mills)
for the indicated number of weeks. Mice were weighed weekly
and food intake was measured over a 3-day period each week.
Feed efficiency was calculated as grams of weight gained per
grams of food consumed. To assess locomotor activity, mice were
habituated to the test room and chamber for 5 days prior to testing
to minimize any stress-induced changes in activity. Spontaneous
locomotor activity was measured using an activity monitor
(AM1051 Activity Monitor, Benwick Electronics) consisting of
a Perspex chamber (32 cm× 20 cm×19 cm) positioned within
a frame equipped with IR beams along its length and width.
Locomotor activity was recorded automatically by counting the
number of beam breaks in the test period. A mouse was considered
mobile if there were two consecutive beam breaks but not if the
same beam was broken twice. Total beam breaks were recorded
in 5 min time-bins over a period of 15 min. The results represent
the accumulative activity over the total 15 min test period.
Physiological measurements
Nose-to-anus length was measured either post-mortem or in
anaesthetized mice, with the observer blinded to the genotype.
Blood samples were collected from mice via tail vein bleeds or
from cardiac puncture performed on terminally anaesthetized
mice. Blood glucose was measured using a glucometer
(Ascensia). Plasma insulin, leptin, T4 (thyroxine), adiponectin
and corticosterone levels were measured using mouse insulin
(Linco), leptin and T4 (Alpha Diagnostic), adiponectin (R&D
Systems) and corticosterone (Enzo Life Sciences) ELISA kits.
Colorimetric assays were used to measure plasma FFA (free fatty
acid; Roche) and cholesterol (Biovision) with TG (triacylglycerol
‘triglyceride’) measured using a Triglyceride Determination kit
(Sigma). Lipids were extracted from 0.3–0.5 g of pooled mouse
faeces by homogenizing in 20 volumes of chloroform/methanol
[2:1 (v/v)] in an Ultra Turrax tissue disrupter (Fisher Scientific).
Total lipids were prepared according to the Folch method [22] and
non-lipid impurities removed by washing with 0.88% KCl. The
weight of lipids was determined gravimetrically after evaporation
of solvent and overnight desiccation under vacuum. Glucose
tolerance tests were performed on mice after a 16 h overnight
fast. Animals were injected intraperitoneally with D-glucose
(2.0 or 1.0 g/kg of body weight) or given D-glucose (3 mg/kg
of body weight) orally and blood glucose levels determined by
glucometer. Insulin tolerance tests were carried out on mice
after a 4 h fast by intraperitoneal injection of 0.75 unit of human
insulin/kg of body weight (Actrapid®, Novo Nordisk) and blood
glucose levels were determined as above. RMR (resting metabolic
rate) was measured at a thermoneutral temperature (30 ◦C) by
indirect open-flow respirometry system (Xentra 1400, Servomex)
as described previously [23]. RQ (respiratory quotient) was
determined from the ratio of the rates of oxygen consumption
and carbon dioxide production. Quantitative determination of Aβ
levels (Aβx-40 and Aβx-42) was performed using the appropriate
[human/rat (mouse) β-amyloid] ELISA kits (Wako). BACE1
activity was determined using a quenched fluorescence assay as
follows. A portion (25 μg) of tissue lysate was added to 50 μl of
assay buffer [0.1M sodium acetate (pH 4)] and 10 μM BACE1
synthetic peptide substrate (β-secretase substrate IV fluorogenic,
Calbiochem), based on the β-secretase cleavage site of the
APP Swedish mutation, in a 96-well plate. The reaction was
incubated at 37 ◦C in the dark and the fluorescence (excitation
wavelength = 350 nm and emission wavelength = 495 nm) was
measured after 1 h. Background activity was subtracted and
results are expressed as RFUs (relative fluorescent units).
Cell culture
C2C12 mouse myoblast cells were grown in DMEM (Dulbecco’s
modified Eagle’s medium, Sigma) supplemented with 10% FBS
(fetal bovine serum), and 1% penicillin and streptomycin at 37 ◦C
in a humidified atmosphere of 95% air and 5% CO2. C2C12
cells were plated at 200000 cells per well on six-well plates in
growth medium [high-glucose DMEM (Invitrogen), 10% (v/v)
FBS (Sera Labs) and 1% (v/v) penicillin and streptomycin
(Gibco)]. The following day cells were moved to differentiation
medium [high-glucose DMEM (Invitrogen), 2% (v/v) horse
serum (Invitrogen) and 1% (v/v) penicillin and streptomycin
(Gibco)] and allowed to differentiate for 5 days before treatment.
For transfection, cells were plated on to 10-cm plates at 500000
cells per plate and transfected with 10 μg of plasmid DNA of
either empty vector (pcDNA3.1) or pcDNA3.1 containing full-
length BACE1 using LipofectamineTM 2000 reagent (Invitrogen),
according to the manufacturer’s instructions. Cells were selected
for 5 days with 1 mg/ml G418 (Sigma–Aldrich), and then plated
and differentiated as described above. For BACE1-inhibitor treat-
ments, cells were differentiated as described for 4 days and treated
with Merck-3 (50 nM β-Secretase Inhibitor IV, Calbiochem)
overnight. Cells were then treated as described above.
Glucose uptake assays
C2C12 myotubes were serum-starved for 2 h followed by insulin
stimulation (100 nM) for 30 min. Insulin-stimulated glucose
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uptake was determined as follows: C2C12 myotubes were washed
twice with HBS [(Hepes-buffered saline); 140 mM NaCl, 20 mM
Hepes, 5 mM KCl, 2.5 mM MgSO4 and 1 mM CaCl2 (pH 7.4)]
and incubated for 10 min in HBS containing 10 μM 2-deoxy-
D-[3H]glucose (1 μCi/ml, PerkinElmer) at room temperature
(20 ◦C). Non-specific uptake was determined by quantifying cell-
associated radioactivity in the presence of 10 μM cytochalasin B
(Sigma–Aldrich). Medium was aspirated and adherent cells were
washed twice with ice-cold 0.9% NaCl. Cells were subsequently
lysed in 50 mM NaOH and cell-associated radioactivity was
quantified using a Beckman LS 6000IC scintillation counter.
Immunoprecipitation and Western blotting
After an overnight fast, mice were injected with 2 units of
insulin/kg of body weight (unless otherwise stated), or an
equal volume of saline, intraperitoneally. Tissues (quadriceps
muscle, liver and perigenital fat) were collected in liquid
nitrogen, 5, 6 and 7 min after injection respectively. C2C12
cells, grown in six-well plates, were exposed to 50 nM Merck-
3 or vehicle for 24 h, prior to incubation with insulin (5 nM) or
vehicle for 30 min. Tissue or cell samples were homogenized in
lysis buffer, and protein isolation, content, immunoblotting and
analysis were performed as described previously [24]. Primary
antibodies used were: anti-BACE1 (Calbiochem or Sigma;
1:1000 dilution), anti-[phospho-PKB (protein kinase B) (Ser473)],
anti-[phospho-IRS (insulin receptor substrate) 1 (Tyr612)], anti-
(total PKB) and anti-IRS1 (Cell Signaling Technology; 1:1000
dilution), anti-[UCP (uncoupling protein) 1] (Abcam; 1:1000
dilution), and anti-BACE2 (R&D Systems; 1:1000 dilution),
anti-tubulin (Sigma; 1:1000 dilution) and anti-(β-actin) (Sigma;
1:10000 dilution).
qRT-PCR (quantitative real-time PCR)
Gene expression was determined by qRT-PCR using TaqMan®.
Total RNA was extracted from frozen tissue using the TRISOL
method (Sigma). A portion (1 μg) of total RNA was used for
first-strand cDNA synthesis using Superscript II (Invitrogen).
For quantitative PCR, 1.25 ng of cDNA was amplified (Prism
7700), using assay-on-demand premixed (Applied Biosystems)
TaqMan® primers and probes [UCP1 (Mm01244861_m1); UCP2
(Mm00627597_m1); and UCP3 (Mm00494077_m1)]. Genes of
interest were normalized to actin (Mm00607929_s1) as a control
gene and are expressed relative to gene expression in the control
group.
Statistics
Comparisons between groups were made using unpaired or paired
two-tailed Student’s t test, one sample Student’s t test, ANCOVA
(analysis of co-variance) or ANOVA with repeated measures
and Bonferroni post-test analysis as appropriate. Results are
means +− S.E.M. P values 0.05 were considered statistically
significant.
RESULTS
BACE1− /− mice have decreased body weight and adiposity
We used BACE1− / − mice produced by targeted deletion of
most of the first coding exon [21]. BACE1 protein was absent
in the cerebral cortex, skeletal muscle and liver of BACE1− / −
mice, whereas heterozygote BACE1 mouse (BACE1+ / − ) tissues
expressed half the amount of BACE1 as tissue from WT
littermates (Figure 1A). BACE1 protein exhibits a single band
at molecular mass of ∼70 kDa, indicative of the mature
(glycosylated) form of the protein [16]. To show that loss of
BACE1 resulted in a functional reduction in APP cleavage,
levels of Aβ were measured in WT and BACE1− / − mice
cerebral cortices. The amounts of Aβx-40 and Aβx-42, the main
enzymatically processed forms of Aβ [10,15,16], were reduced
significantly in the BACE1− / − mice cortex compared with WT
controls (Figure 1B). The remaining Aβ peptides observed in
the BACE1− / − mice cortex are probably derived from BACE2
activity, which is present in glial cells [25] and is detectable in
BACE1− / − mice cortex samples (Figure 1B), or other aspartic
protease activity present in the tissue. In our hands, BACE1− / −
mice are viable and fertile, and lived longer than 21 months
without overt signs of any abnormalities. No gross or histological
differences were detected in the brain, muscle, liver, heart or
pancreas of BACE1− / − mice (results not shown). BACE1− / −
mice (6–8 weeks old) fed a regular chow diet were significantly
lighter than their WT littermates. This weight difference was
maintained during growth for male and female BACE1− / − mice
(Figures 1C and 1D) and at 1 year of age they weighed 18%
(P = 0.004) and 16% (P < 0.001) less respectively than their WT
littermates. The average length of BACE1− / − mice was unaltered
compared with their WT littermates (Figure 1E). Although no
evidence of sexual dimorphism was observed, we focused our
research predominantly on male mice. BACE1+ / − mice did
not exhibit any difference in body mass at 10 weeks of age
or when body mass was followed for an additional 24 weeks
compared with their WT littermates (Supplementary Figure S1A
at http://www.BiochemJ.org/bj/441/bj4410285add.htm).
BACE1− / − mice had reduced relative amounts of perigenital fat
compared with their WT littermates (Supplementary Figure S1B),
and qMR (quantitative magnetic resonance) scanning revealed
they had decreased total body fat (Figure 1F). BACE1− / − mice
exhibited elevated heart and brain mass, but normal liver and
reduced BAT (brown adipose tissue) mass, relative to their total
body mass (Supplementary Figures S1C–S1F). Consistent with
their reduced body fat, BACE1− / − mice had decreased (46%
lower) serum leptin (Figure 1G), although they displayed no
difference in serum levels of FFA, TG or cholesterol compared
with WT mice (Table 1). These results indicate that the reduced
body mass of BACE1− / − mice is due to decreased lipid content.
Cumulative food intake of BACE1− / − mice was unchanged
compared with their WT littermates (Figure 2A), whereas relative
food intake was significantly higher (Figure 2B). This resulted in
an overall reduced feed efficiency in BACE1− / − mice compared
with WT controls (Figure 2C). Although the mean mass of
faeces was unchanged between BACE1− / − mice and littermate
controls (Figure 2D), the lipid content of faeces from BACE1− / −
mice was reduced significantly (Figure 2E). Indirect calorimetry
showed that BACE1− / − mice had a higher RMR than WT mice
(Figure 2F), ∼7% more than expected for their body mass and
sex, and this was accompanied (Figure 2G) by an increased RQ.
We were unable to detect a difference in locomotor activity
between BACE1− / − , BACE1+ / − and WT mice (Figure 2H).
Plasma levels of T4 were unchanged in BACE1− / − mice (Table 1).
BACE1− /− mice have improved glucose disposal and increased
insulin sensitivity
Fasting blood glucose levels were unaltered in BACE1− / − mice,
whereas ad libitum-fed blood glucose levels were significantly
lower than that of their WT littermates (Figure 3A). Fasting
plasma insulin levels were also unchanged (Table 1). IGTTs
(intraperitoneal glucose tolerance tests) showed that BACE1− / −
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Figure 1 BACE1− /− mice exhibit reduced adiposity
(A) BACE1 protein levels in BACE1− / − , BACE1+ / − and WT mice, as shown by representative immunoblots of mouse cerebral cortex, skeletal muscle and liver. The histogram (bottom panel)
shows mean normalized levels of BACE1 in cortex from WT, BACE1+ / − and BACE1− / − mice following 20 weeks fed on the regular chow diet. WT, n = 11; BACE1+ / − , n = 11; BACE1− / − ,
n = 12. (B) Representative immunoblots of BACE2 in WT, BACE1+ / − and BACE1− / − mouse cerebral cortices. The histogram (bottom panel) shows levels of Aβx-42 and Aβx-40 in the cerebral
cortex of WT and BACE1− / − mice. WT, n = 5; BACE1− / − , n = 6. Molecular mass is given in kDa on the left-hand side. Male (C) and female (D) body mass curves of age-matched WT littermate
and BACE1− / − mice fed on a regular chow diet, monitored over a period of 45 weeks from 9 weeks of age. The results in (C) and (D) are means +− S.E.M. from 9–12 animals of each genotype. (E)
Male BACE1− / − mice have unaltered body length compared with the WT controls. WT, n = 20; BACE1− / − , n = 19. (F) Percentage body fat determined by qMR imaging in 8-month-old male WT
and BACE1− / − mice. WT, n = 5; BACE1− / − , n = 7. (G) Fasting blood leptin levels in 8-month-old male mice of the indicated genotypes. WT, n = 12; BACE1− / − , n = 15. Results are means +−
S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
Table 1 Metabolic characteristics of WT and BACE1− /− mice fed either a regular chow or an HFD
Male BACE1− / − or WT mice were fed on regular chow or an HFD ad libitum. Serum was collected from fasted 8-month-old mice, and the indicated metabolic parameters measured. Results are
means- +− S.E.M. from measurements obtained from 7–13 animals per group.
WT BACE1− / −
Parameter Diet... Regular High fat Regular High fat
Serum insulin (pg/ml) 277 +− 23 1056 +− 179* 267 +− 20 414 +− 72*†
Serum adiponectin (μg/ml) 9.93 +− 0.57 11.05 +− 1.22 10.87 +− 0.86 10.02 +− 0.60
Serum cholesterol (ng/ml) 4.86 +− 0.21 8.48 +− 0.48* 4.75 +− 0.19 7.65 +− 0.28*
Serum FFA (mM) 0.31 +− 0.03 0.36 +− 0.06 0.28 +− 0.03 0.29 +− 0.02
Serum TG (mM) 1.21 +− 0.14 1.28 +− 0.12 1.26 +− 0.12 1.35 +− 0.07
Serum T4 (μg/dl) 8.44 +− 0.35 7.75 +− 0.49 7.62 +− 0.25 7.70 +− 0.78
Serum corticosterone (ng/ml) 68.2 +− 11.8 55.8 +− 8.1 111.5 +− 22.4 94.1 +− 7.1 †
*P < 0.05 compared with regular chow.
†P < 0.05 compared with corresponding WT.
mice had increased glucose clearance from the peripheral
circulation compared with their WT littermates (Figures 3B
and 3C). One-year-old BACE1− / − mice also had increased
glucose disposal following OGTTs (oral glucose tolerance tests)
in comparison with age-matched WT controls (Figures 3D
and 3E). BACE1+ / − mice, despite fasting and fed glucose
levels equivalent to WT controls (Supplementary Figures S2A
and S2B at http://www.BiochemJ.org/bj/441/bj4410285add.htm),
also exhibited increased glucose disposal (Figures 3B and 3C).
BACE1− / − , but not BACE1+ / − , mice showed a significantly
greater decrease in blood glucose during ITTs (insulin tolerance
tests) at all of the time points examined (Figure 3F). Thus
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Figure 2 BACE1− /− mice have increased relative food intake and energy
expenditure
(A) Cumulative food intake, measured over 12 weeks, in 3-month-old male mice of the indicated
genotypes. (B) Food intake per mouse per week normalized by body mass (relative food intake).
(C) BACE1− / − mice have decreased feed efficiency compared with the WT controls. Results in
(A–C) are from 5–7 animals of each genotype. (D) Mean mass of faeces over 24 h for WT and
BACE1− / − mice. (E) Lipid content of faeces in WT and BACE1− / − mice. Results in (D) and
(E) are from seven animals of each genotype. (F) Energy expenditure determined by indirect
calorimetry in 8-month-old WT and BACE1− / − mice. (G), BACE1− / − mice have an increased
RQ compared with the WT mice. Results in (F) and (G), WT, n = 14 and BACE1− / − , n = 12.
(H) Effect of genotype on locomotor activity. WT, n = 9; BACE1+ / − , n = 10; BACE1− / − ,
n = 6. Results are means +− S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
BACE1− / − mice have increased whole-body insulin sensitivity
in comparison with their littermate controls.
BACE1− /− mice are protected from HFD-induced obesity and
insulin resistance
When BACE1− / − mice were challenged for 20 weeks with
an HFD (45% of total calories derived from fat), mass
accumulation was significantly reduced compared with age-
matched WT controls (Figure 4A). The relative increase in
body mass at the end of the HFD was 49.8% and 31.4% for
WT and BACE1− / − mice respectively. Indeed the final masses
of BACE1− / − mice after the HFD were comparable with age-
matched WT mice on a regular chow diet (mass of HFD-fed
BACE− / − mice = 32.7 +− 1.2 g, mass of regular-chow-diet-fed
WT mice = 31.6 +− 0.5 g). Cumulative food intake was slightly
less for HFD-fed BACE1− / − mice (Figure 4B), although relative
food intake was increased and feed efficiency decreased compared
with WT mice (Supplementary Figures S2E and S2F). qMR
analysis confirmed that the fat mass of HFD-fed BACE1− / −
mice, although increased (P < 0.01) relative to age-matched
Figure 3 Improved insulin sensitivity and glucose homoeostasis in
BACE1− /− mice
(A) Fasted and fed blood glucose levels in 8-month-old male mice of the indicated genotypes
(n = 11–18). (B) IGTTs were performed on 8-month-old male mice of the indicated
genotypes (n = 10–12). (C) Quantification of the AUC (area under the curve) for the total
glycaemic excursions shown in (B). (D) OGTT in 12-month-old male WT and BACE1− / − mice
with quantification of the total glycaemic excursion shown in (E). WT, n = 11; BACE1− / − ,
n = 9. (F) ITT for 8-month-old male mice of the indicated genotypes (n = 12–17). Results are
means +− S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
BACE1− / − mice on a regular chow diet, was significantly reduced
compared with HFD-fed WT littermates (Figure 4C). Although
leptin levels increased (P < 0.001; compared with the results
shown in Figure 1G) in WT and BACE1− / − mice following
the HFD, BACE1− / − leptin levels were 60% lower than WT
mice (Figure 4D), as expected from their reduced adiposity.
Thus BACE1 contributes to body mass regulation in mice and
the absence of this protein provides protection against excessive
weight gain on an HFD.
A high proportion of C57Bl6/J mice fed on an HFD go on
to display obesity-induced impairment of glucose homoeostasis
and insulin resistance [26]. Indeed, the HFD significantly
increased fasted and fed blood glucose concentrations in WT
and BACE1− / − mice compared with their regular-chow-fed
counterparts, although BACE1− / − mice maintained significantly
lower glucose levels than WT littermates under both conditions
(Figure 4E). The levels of serum FFAs and TG were unchanged
in WT and BACE1− / − mice, although cholesterol levels were
increased in both groups on the HFD (Table 1). HFD-fed WT
mice showed a 4.5-fold increase in serum insulin concentrations,
whereas BACE1− / − mice, despite having an identical serum
insulin level to WT mice fed on regular chow, displayed less than
a 2-fold increase (Table 1). Consistent with these results, HFD-
fed WT mice exhibited impaired glucose disposal compared with
regular-chow-fed WT mice, whereas HFD-fed BACE1− / − mice
cleared glucose from the peripheral circulation significantly better
than the HFD-fed WT controls (Figures 4F and 4G). The HFD-
fed BACE1− / − mice also maintained a higher insulin sensitivity
compared with their WT littermates (Figure 4H). Corticosterone
levels were similar for WT and BACE1− / − mice fed on the regular
chow diet and were raised for both genotypes following the HFD,
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Figure 4 HFD-fed BACE1− /− mice are less susceptible to weight gain and loss of glucose homoeostasis
(A) Body mass gain of age-matched male WT littermate and BACE1− / − mice fed on an HFD, monitored over a period of 20 weeks from 5 months-of-age. (B) Cumulative food intake, measured over
20 weeks, of age-matched male WT littermate and BACE1− / − mice fed on an HFD. Results in (A) and (B) are means +− S.E.M. from 6–11 animals of each genotype. (C) The percentage body fat
determined by qMR imaging in 10-month-old male WT and BACE1− / − mice following 20 weeks of the HFD. WT, n = 7; BACE1− / − , n = 11. (D) Fasting blood leptin levels in 10-month-old male
mice of the indicated genotypes, following 20 weeks of a HFD. WT, n = 11; BACE1− / − , n = 11. (E) Fasting and fed blood glucose levels in 8-month-old male mice of the indicated genotypes,
following 20 weeks on a HFD (n = 7–11). (F) IGTTs were performed on 8-month-old male mice of the indicated genotypes following 20 weeks of the HFD. WT, n = 7; BACE1− / − , n = 5 (G)
Quantification of the AUC (area under the curve) for the total glycaemic excursions shown in (F). (H) ITTs for 8-month-old male mice of the indicated genotypes, following 20 weeks of an HFD. WT,
n = 7; BACE1− / − , n = 5. Results are means +− S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
with the increase showing significance only for the BACE1− / −
mice (Table 1).
BACE1+ /− mice exhibit time-dependent resistance to diet-induced
obesity
BACE1+ / − mice fed on the HFD initially exhibited resistance
to mass gain (Figure 5A), but by the end of the HFD period
there was no significant difference in their mean body mice
compared with the HFD-fed WT controls (mass of the BACE1+ / −
mass = 42.8 +− 2.6 g, mass of the WT mice = 46.2 +− 0.5 g;
P > 0.05). Thus BACE1+ / − mice, although initially comparatively
resistant to mass gain when fed on the HFD, eventually exhibit
the same level of adiposity as WT mice. In addition, although
BACE1+ / − mice after 10 weeks of being fed on the HFD displayed
better glucose disposal and insulin sensitivity (Figures 5C and 5D)
compared with their HFD-fed WT counterparts, these metabolic
improvements were attenuated by the end of the HFD period
(Figures 5E and 5F). Indeed, the 20-week HFD-fed BACE1+ / −
mice demonstrated a non-significant trend to lower fasted, but did
exhibit reduced fed, blood glucose levels compared with the HFD-
fed WT controls (Supplementary Figures S2C and S2D). These
time-dependent changes in adiposity and glucose homoeostasis
during the HFD were observed for BACE1+ / − mice, and not
BACE1− / − mice. This raised the possibility that dietary fat content
influences BACE1 levels and/or activity in peripheral tissues.
In support of this hypothesis, a 20-week HFD was shown to
increase BACE1 protein levels in skeletal muscle of WT and
BACE1+ / − mice (Figure 5F) and to increased levels of Aβx-42
(but not Aβx-40; results not shown) in the cerebral cortex of WT
mice, but not BACE1− / − mice (Supplementary Figure S3 at
http://www.BiochemJ.org/bj/441/bj4410285add.htm). However,
the low levels of Aβ in control peripheral tissues precluded the use
of the Aβ assay to monitor BACE1 activity. Thus we determined
BACE1 activity directly using a quenched fluorescence assay and
demonstrated that BACE1 protease activity in skeletal muscle
and liver of WT and BACE1+ / − mice was significantly increased
by the HFD, compared with BACE1 activity in tissues of age-
matched regular-chow-fed WT and BACE1+ / − mice (Figure 5G
and 5H).
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Figure 5 BACE1+ /− mice show time-limited resistance to an HFD
(A) Body mass gain of age-matched male WT littermate and BACE1+ / − mice fed on an HFD, monitored over a period of 20 weeks from 3 months of age. Note that P < 0.05 for weeks 4–14 only.
WT, n = 8; BACE1+ / − , n = 7. IGTT (B) and ITT (C) for WT and BACE1+ / − mice, after 10 weeks on an HFD. IGTT (D) and ITT (E) for WT and BACE1+ / − mice, after 20 weeks on an HFD. WT,
n = 8; BACE1+ / − , n = 7 for (B)–(E). (F) Representative immunoblots of BACE1 in skeletal muscle of male WT and BACE1+ / − mice following 20 weeks on the regular chow (RC) diet or the HFD.
The histogram shows mean normalized levels of BACE1 in skeletal muscle (n = 9–15). Molecular mass is given in kDa on the left-hand side. BACE1 activity for skeletal muscle (G) and liver (H) of
WT and BACE1+ / − mice following 20 weeks on the regular chow diet or the HFD (n = 6–11). Results are means +− S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
BACE1 reduction increases the insulin sensitivity of liver and
skeletal muscle, and increases glucose uptake in C2C12 cells
The results from the ITTs indicated that BACE1 influences the
insulin signalling pathway in tissues responsible for peripheral
glucose clearance. To assess insulin signalling strength we
measured phospho-PKB levels in skeletal muscle and liver
following intraperitoneal injection of insulin (2 units/kg of body
weight). In the basal state, phospho-PKB levels were unchanged
in BACE1− / − and BACE1+ / − mice compared with the WT
controls. However, in response to insulin stimulation, BACE1− / −
and BACE1+ / − mice displayed increased phospho-PKB levels
in skeletal muscle and liver compared with their WT littermates
(Figure 6). Thus removal or reduction in BACE1 increases insulin
signalling in skeletal muscle and liver in vivo. Total PKB levels
were unchanged in insulin-stimulated or unstimulated muscle and
liver of BACE1− / − and BACE1+ / − mice in comparison with WT
tissues (Figure 6). To demonstrate that altered insulin sensitivity
is directly associated with reduced BACE1 activity we used the
cell-permeant BACE1 inhibitor Merck-3 [27] to treat the mouse
skeletal muscle cell line C2C12. C2C12 cells express BACE1,
exhibiting a single band of ∼70 kDa (Figure 7A). Merck-3 has
an IC50 value of ∼30 nM to inhibit the cleavage of APP in cells
[28]. C2C12 cells, in the absence and presence of 50 nM Merck-
3, were stimulated with 5 nM insulin and phospho-PKB levels
monitored. Merck-3, in the absence of insulin, had no effect
on phospho-PKB, whereas insulin-stimulated phospho-PKB was
enhanced in cells treated with Merck-3 (Figure 7B). Merck-3
had no effect on total PKB levels in these cells (Figure 7B). To
examine whether the increased phospho-PKB reflected increased
insulin receptor kinase activity, the tyrosine phosphorylation of
IRS-1 (phospho-IRS-1) in insulin-stimulated C2C12 cells was
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Figure 6 Increased PKB phosphorylation by insulin in muscle and liver BACE1− /− mice
Representative immunoblots of insulin-stimulated phosphorylation of PKB at Ser473 from the skeletal muscle (A) and liver (B) of 16–20-week-old WT, BACE1+ / − and BACE1− / − mice, 5 and
6 min after insulin injection respectively. The histograms below the immunoblots show the normalized means +− S.E.M of the immunoblots for the skeletal muscle and liver of the indicated genotypes
respectively. Results are means +− S.E.M. from 7–19 animals of each genotype. *P < 0.05; **P < 0.01; ***P < 0.001. Molecular mass is given in kDa on the left-hand side.
Figure 7 Inhibition of BACE1 increases insulin signalling in C2C12 muscle cells
(A) Representative immunoblots showing the presence of BACE1 protein in the mouse C2C12 skeletal muscle cell line under control conditions (EV) and following transfection with adenovirus
containing Myc-His-tagged BACE1 (B1). (B–D) Mouse C2C12 muscle cells were exposed to the BACE1 inhibitor Merck-3 for 24 h, prior to cells being stimulated with saline or insulin for 30 min. (B)
Representative immunoblots of insulin-stimulated phosphorylation of PKB at Ser473 in treated and untreated C2C12 cells. The histograms show the normalized means +− S.E.M. of the immunoblots
(n = 10). (C) Representative immunoblots of IRS-1 and phosphorylated IRS-1 at Tyr612 in treated and untreated C2C12 skeletal muscle cells. The histograms show the normalized means +− S.E.M. of
the immunoblots (n = 8). Molecular mass is given in kDa on the left-hand side. (D) Insulin-stimulated 2-deoxyglucose uptake in treated and untreated C2C12 cells, expressed relative to the uptake
in the absence of insulin (n = 11). (E) Relative BACE1 activity in C2C12 cells transfected with empty vector (Cont) or Myc-His-tagged BACE1 (n = 9). (F) Insulin-stimulated 2-deoxyglucose uptake
in C2C12 cells, transfected with empty vector (Cont) or Myc-His-tagged BACE1, expressed relative to uptake in the absence of insulin (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001.
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measured. Although insulin enhanced phospho-IRS-1 levels in
control and Merck-3-treated cells, no difference in phospho-IRS-1
or total IRS levels was observed in Merck-3-treated and untreated
muscle cells (Figure 7C), indicating that BACE1 may exert its
effect distal to the insulin receptor and its adaptor protein. We
next confirmed that altering BACE1 levels and activity in C2C12
muscle cells correlated with changes in glucose uptake. Thus 2-
deoxyglucose uptake was measured in C2C12 cells following 24 h
of treatment with Merck-3 (50 nM). The presence of the BACE1
inhibitor significantly improved insulin-stimulated glucose uptake
in C2C12 myotubes (Figure 7D). Furthermore, when BACE1
was over-expressed in C2C12 muscle cells (Figure 7A), which
resulted in a small, but significant, increase in BACE1 activity
(Figure 7E), there was a significant reduction in insulin-stimulated
2-deoxyglucose uptake (Figure 7F).
BACE1− /− mice exhibit increased UCP expression
The loss of BACE1 globally in mice results in a lean phenotype,
which is associated with reduced fat content, increased energy
expenditure and reduced metabolic efficiency, coupled with
improved glucose disposal and higher insulin sensitivity. A
potential explanation for this phenotype is that removal of BACE1
from highly metabolically active tissues such as BAT and skeletal
muscle causes inefficient energy metabolism through modulation
of respiratory function (uncoupling). UCPs are considered to be
major contributors to diet-induced thermogenesis and decreased
energy efficiency [29]. Although the mass of BAT is less
in BACE1− / − mice (Supplementary Figure S1D) we found
no difference in BAT morphology, compared with the WT
littermate controls (Figure 8A). However, UCP1 protein levels
were increased in BAT from BACE1− / − mice compared with their
WT littermates when fed on regular chow or the HFD (Figure 8B).
It has also been reported that brown adipocytes may be present in
WAT (white adipose tissue) and skeletal muscle of rodents [30,31].
As the expression of UCP1 was expected to be much lower in these
tissues we performed qRT-PCR (TaqMan®) to measure UCP1
mRNA levels. The levels of UCP1 mRNA were extremely low
in WAT and skeletal muscle, and these were not consistently
altered in BACE1− / − mice compared with their WT littermates
fed on either regular chow or HFD (results not shown). As skeletal
muscle plays a major role in whole-body energy consumption
and has the capacity for thermogenesis, we examined this tissue
further for evidence of changes driven by the loss of BACE1
and/or the HFD that may link to induction of skeletal muscle
thermogenesis. For example, activation of skeletal muscle AMPK
(AMP-activated protein kinase) has been linked to skeletal muscle
thermogenesis [32] and numerous studies have demonstrated an
association between increased expression of UCP2 and UCP3
with uncoupled mitochondrial respiration, protection against fat
gain when fed on an HFD and improved muscle insulin sensitivity
[33–35]. Skeletal muscle AMPK activity of BACE1− / − mice was
unaltered in comparison with their WT littermates (Figure 8C).
However, UCP2 and UCP3 mRNA levels were increased in
skeletal muscle of BACE1− / − mice relative to their WT littermates
(Figures 8D and 8E). Furthermore, exposure to the HFD increased
UCP3 mRNA levels (with a non-significant trend for increased
UCP2 mRNA) in skeletal muscle from WT mice and this effect
of the HFD was exaggerated markedly in skeletal muscle of
BACE1− / − mice (Figures 8D and 8E).
DISCUSSION
Loss or reduction of BACE1 in mice enhanced glucose tolerance
and increased insulin-stimulated glucose disposal. HFD-fed WT
Figure 8 Increased UCP levels in BACE1− /− mice
(A) H&E (haematoxylin and eosin) staining of BAT from WT and BACE1− / − mice fed on a regular
chow diet for 20 weeks. Scale bar represents 50 μm. (B) Representative immunoblots of UCP1,
with tubulin as loading control, from BAT of WT and BACE1− / − mice following 20 weeks on the
regular chow diet and HFD. The histogram shows mean normalized UCP1 protein expression
in WT and BACE1− / − BAT on regular and high-fat diet. Results are means +− S.E.M. for 5–11
animals under each condition. Molecular mass is given in kDa on the left-hand side. (C) AMPK
activity measured from skeletal muscle of WT and BACE1− / − mice following 20 weeks on the
regular chow diet. WT, n = 8; BACE1− / − , n = 8. Mean normalized UCP2 mRNA (D) and UCP3
mRNA (E) expression in skeletal muscle of WT and BACE1− / − mice, following 20 weeks on the
regular diet or the HFD. Results are means +− S.E.M. from 8–14 animals under each condition.
*P < 0.05; **P < 0.01; ***P < 0.001.
mice displayed insulin resistance as exemplified by a 4-fold
increase in fasted insulin, raised fasted and fed blood glucose
levels concomitant with impaired glucose disposal following a
bolus injection of glucose. Although BACE1− / − mice responded
to HFD challenge in a similar manner to WT mice, the absolute
levels of glucose, leptin and insulin were all significantly less than
for HFD-fed WT mice. Furthermore, HFD-fed BACE1− / − mice
maintained a significantly improved glucose disposal and insulin
sensitivity compared with HFD-fed WT mice. Although regular-
chow-fed BACE1+ / − mice showed no difference in body mass and
fasted or fed glucose levels, they had significantly better glucose
disposal compared with the control mice. Interestingly, HFD-
fed BACE1+ / − mice revealed initial resistance to increased body
mass in association with better whole-body glucose disposal and
insulin sensitivity. However, by the end of the HFD, BACE1+ / −
mice had a body mass indistinguishable from HFD-fed WT mice,
with evidence of reduced glucose tolerance and insulin sensitivity.
A possible explanation was indicated by the observation that
BACE1 protein levels and BACE1 activity in skeletal muscle
and liver of HFD-fed WT and BACE1+ / − mice were significantly
higher than their lean controls. Thus dietary fat content and/or fat
levels may influence whole-body insulin sensitivity and glucose
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disposal through modification of BACE1 levels and activity in
insulin-sensitive tissues such as skeletal muscle and liver.
These results suggested that BACE1 plays a role in the insulin
signalling pathway. Indeed, BACE1 levels increase with age and
are greater in brains of AD patients [14,15] and correlates with
reduced insulin receptor binding and insulin sensitivity compared
with age-matched non-AD controls [8,36,37]. Furthermore,
suppression of brain glucose utilization and induction of
insulin resistance in rats by intracerebroventricular injection of
streptozotocin is associated with pathological and behavioural
deficits similar to those observed in AD patients [38,39]. In
addition, induction of peripheral insulin resistance in an AD
transgenic mouse model reduced brain insulin receptor signalling
and increased Aβ content and amyloid plaque burden [9].
Although loss or reduction of BACE1 is insufficient to activate
PKB in liver or skeletal muscle at fasted levels of insulin, insulin
stimulation increased PKB activation in skeletal muscle and liver
of BACE1− / − and BACE1+ / − mice, consistent with a higher
insulin sensitivity in these tissues.
Importantly, the enhancement of insulin signalling and glucose
uptake was replicated in a skeletal muscle cell line by
pharmacological inhibition of BACE1 activity with Merck-3.
Furthermore, increasing BACE1 levels and activity in this skeletal
muscle cell line resulted in decreased 2-deoxyglucose uptake.
These results indicate that the effects of altered BACE1 levels and
activity on insulin signal propagation and glucose uptake are likely
to be cell autonomous. The effect of BACE1 inhibition in skeletal
muscle and liver is commensurate with the reduced glucose
levels, enhanced glucose disposal and higher insulin sensitivity
of BACE1− / − mice, particularly when exposed to an HFD. At
present, the molecular mechanism(s) by which BACE1 reduction
alters insulin sensitivity is unclear. BACE1 along with γ -secretase
generates Aβ. Extracellular Aβ exists as soluble oligomers [also
known as ADDLs (Aβ-derived diffusible ligands], which are
toxic to neurons, and are reported to decrease insulin signalling
by inhibition of insulin binding to insulin receptors [40] or
by ADDL-mediated insulin receptor internalization [41]. It has
also been proposed that intracellular Aβ accumulation inhibits
insulin receptor signalling by interfering with PKB activation
by inhibition of its upstream kinase, PDK (phosphoinositide-
dependent kinase) [42]. Our finding that Merck-3 has no effect
on insulin-stimulated phospho-IRS-1 (Tyr612) levels does not
support a mechanism by which insulin binding or insulin
receptor numbers are modified. In contrast, the increased insulin-
stimulated phospho-PKB in the liver and muscle cells is consistent
with an enhanced PDK–PKB interaction. As multiple substrates
for BACE1 exist [16,43] and Aβ targets numerous intracellular
signalling pathways [44], it is feasible that tissue- or cell-specific
outcomes depend on the relative expression and cellular location
of a particular substrate or, if found to be APP-dependent, the
ability of Aβ to interact with individual signalling complexes.
Clearly, much more detailed analysis of BACE1 activity and
substrate sensitivity in individual tissues and cells is required.
BACE1− / − mice are leaner with less body fat than the WT
controls, a phenotype they maintained throughout the study period
(and which was present in animals more than 21 months old;
results not shown). In contrast, BACE1+ / − mice exhibited growth
curves and body mass equivalent to the WT controls. Exposure to
an HFD resulted in WT and BACE1− / − mice gaining body mass,
although the BACE1− / − mice remained leaner throughout the
HFD period. However, BACE1+ / − mice, although maintaining a
lower body mass for the first few weeks of the HFD, eventually
gained mass so that by the end of the 20 weeks of HFD they
were the same mass as their WT littermates. The increase in
body mass in WT and BACE1+ / − mice was associated with
increased tissue BACE1 levels and activity. Clearly, further studies
are required to determine whether there is a causal relationship
between BACE1 activity and susceptibility to mass gain and loss
of glucose homoeostasis. The absolute amount of regular chow
consumed by BACE1− / − mice did not differ from WT mice and on
the HFD was only marginally less than WT mice. However, when
adjusted for body mass, BACE1− / − mice consumed more than
the WT mice on either diet, indicating they are less metabolically
efficient. BACE1− / − mice have reduced levels of leptin when fed
on regular chow and the HFD, consistent with their lower levels
of body fat, which may explain the higher relative food intake
of BACE1− / − mice. BACE1− / − mice exhibited no difference in
blood lipid levels or stool mass, although they had less lipid in
their stools compared with the WT mice. These results, along with
the decreased adiposity and resistance to diet-induced obesity,
suggested that BACE1− / − mice exhibit higher energy expenditure.
Indeed, BACE1− / − mice had a higher RMR with no change
in serum T4 levels compared with the controls, indicating that
thyroid-hormone-mediated changes in metabolism are unlikely
to explain this outcome. The increased RMR was detected
after appropriate normalization for the effects of body mass
and sex using ANCOVA. Normalization of energy expenditure
in relation to body mass is a long-standing issue in the
interpretation of energy expenditure data [45,46] and ANCOVA
is the most appropriate approach to overcome such problems
[47]. As our measurements only addressed differences in resting
metabolism, although energy balance is a consequence of resting,
activity and thermoregulatory demands, more detailed studies
of energy regulation by BACE1− / − mice are clearly required.
Nevertheless, we were unable to detect any effect of genotype
on locomotor activity in agreement with a previous study of this
line of BACE1− / − mice [21]. Their higher metabolic rate was
accompanied by an increased RQ, indicating that BACE1− / − mice
at rest utilized a higher carbohydrate-to-fat ratio than did the WT
mice. This effect was unexpected since mice that are resistant to
fat deposition frequently show increased fat oxidation rates. The
elevated levels of carbohydrate oxidation, however, may reflect
their enhanced capacity to dispose of glucose.
One potential mechanism that could explain the metabolic
inefficiency and increased energy expenditure of BACE1− / −
mice is increased thermogenesis. BAT and skeletal muscle are
important sites for the induction of thermogenesis with the
UCPs intimately involved in this process. Indeed loss of UCP1
in mice results in an increased susceptibility to diet-induced
obesity with age [48], and ectopic expression of UCP1 via the
presence of brown adipocytes in skeletal muscle protects mice
from diet-induced mass gain [31]. We found that UCP1 protein
levels are increased in BAT of BACE1− / − mice, an outcome
enhanced by the HFD, indicative of raised thermogenesis and
energy expenditure. Although we could not detect any increase
in UCP1 mRNA or protein levels in WAT or skeletal muscle
of BACE1− / − mice, we observed increased levels of UCP2 and
UCP3 mRNA in skeletal muscle of BACE1− / − mice, which were
enhanced by high-fat feeding. The exact physiological roles for
UCP2 and UCP3 are presently unclear, with their role in adaptive
thermogenesis questioned and alternative functions proposed,
including acting as regulators of muscle lipid metabolism and
reactive oxygen species production [49]. Importantly within the
context of our results and irrespective of exact mechanism, it
has been shown that decreased expression of UCP3 in skeletal
muscle is associated with insulin insensitivity, whereas UCP3
overexpression improves muscle insulin sensitivity and protects
against diet-induced obesity [33–35]. A mechanism that may, at
least in part, underlie the increased expression of UCPs is that loss
of BACE1 centrally could result in an increased sympathetic drive
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to peripheral tissues. Indeed increased release of noradrenaline
from sympathetic nerve terminals causes increased activity of
BAT β3-adrenoceptors, which signals via PKA (protein kinase A)
to drive expression of UCP1 [50].
Taken together, the results of the present study indicate that
deletion or reduction of BACE1 not only renders mice lean and
insulin-sensitive when fed on a regular chow diet, but also causes
them to be, at least partially, protected against the metabolic
derangement caused by chronic exposure to nutrient excess, in
the form of an HFD. These actions may be mediated, at least
in part, by increased expression of uncoupling proteins in BAT
and skeletal muscle, resulting in increased thermogenesis and
improved insulin sensitivity. Consequently, strategies to maintain
reduced BACE1 levels and activity may be sufficient to ameliorate
the adverse metabolic consequences of an HFD, particularly in
individuals more susceptible to Type 2 diabetes.
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Reduction in BACE1 decreases body weight, protects against diet-induced
obesity and enhances insulin sensitivity in mice
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Figure S1 Body mass of BACE1+ /− , and tissue mass of BACE1− /− mice
compared with their WT littermates
(A) Body mass curves of age-matched WT littermates with BACE1+ / − mice fed on a regular chow
diet and monitored over a period of 24 weeks from 9 weeks of age. Results are means +− S.E.M.
from 7–8 animals of each genotype. The relative masses (expressed as the percentage of
total body mass) of perigenital fat (B), brain (C), BAT (D), heart (E) and liver (F) for WT and
BACE1− / − mice are shown. Results are means +− S.E.M. from 5–7 animals of each genotype.
*P < 0.05.
Figure S2 Comparison of the effects of diet on WT, BACE1+ /− and
BACE1− /− mice
Fasted (A) and fed (B) blood glucose levels of 8-month-old male mice of the indicated genotypes
fed on a regular chow diet (n = 6–10). Fasted (C) and fed (D) blood glucose levels of
10-month-old mice of the indicated genotypes fed on an HFD for 20 weeks. (E) Food intake
per mouse per week normalized by body mass (relative food intake) for mice of the indicated
genotypes fed on an HFD. (F) BACE− / − mice on a HFD have decreased feed efficiency
compared with the WT controls. Results are means +− S.E.M. from 11–14 animals of each
genotype. **P < 0.01;*P < 0.05.
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Figure S3 A 20-week HFD was shown to increase levels of Aβx-42 in the
cerebral cortices of WT mice, but not BACE1− /− mice
Results from an ELISA showing the level of Aβx-42 (normalized to mean WT, normal chow diet
amount) in the cerebral cortices of WT and BACE− / − mice fed on a regular chow (RC) diet or
an HFD. WT, n = 5; BACE− / − , n = 6. Results are means +− S.E.M. *P < 0.05.
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